Compare BIO-TECHNE Corp (TECH) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Xpeng Inc - ADR — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Xpeng Inc - ADR trades at $11.72 (market cap $11.49B). The key difference: BIO-TECHNE Corp and Xpeng Inc - ADR are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| TECH | XPEV | |
|---|---|---|
Market Cap | $11.24B | $11.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $72.29 | $28.07 |
52-Week Low | $43.31 | $11.68 |
Enterprise Value | $11.32B | $13.62B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
XPeng (XPEV) trades at $12.13, up 3.85% in the last session, with a bearish technical signal from moving averages but oversold RSI levels. The company reported revenue of $76.72 billion in 2025, with narrowing losses and a negative net income margin of -3.06%. Recent news highlights expansion into robotics and autonomous vehicles, with July 2026 deliveries up 4% year-over-year (PRNewsWire, August 1, 2026).
The outlook is mixed: analyst consensus is bullish with a $17.00 price target (64.7% buy ratings), but risks include persistent losses, high debt-to-asset ratio of 13.63 (2025), and intense EV competition. Upside potential hinges on new model launches and global growth, while cash flow volatility and macroeconomic pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
